Motley Fool: Investors may consider Pfizer as good medicine spokesman.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from spokesman.com Daily Mail and Mail on Sunday newspapers.
The company on Wednesday forecast revenue from its COVID-19 vaccine and treatment to be $8 billion in 2024, a far cry from the $57 billion in 2022. In March, Pfizer announced a $43 billion acquisition of drugmaker Seagen to bring into its fold four approved cancer therapies. Last year, the company struck an $11.6 billion deal for migraine drug maker Biohaven Pharmaceutical Holding and bought Global Blood Therapeutics for $5.4 billion, adding sickle cell disease treatment Oxbryta to its pipeline.